NAD+ — Research Reference

NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme found in all living cells and central to cellular energy metabolism. It is important to note at the outset: NAD+ is not a peptide. It is a dinucleotide — a molecule composed of two nucleotides joined through phosphate groups. It is included here because NAD+ supplementation is closely associated with the peptide research community, is frequently discussed alongside compounds such as Epitalon, GHK-Cu, MOTS-c, and SS-31 in longevity research contexts, and is commonly sourced and administered through the same research channels.

Quick Reference

Parameter	Reported Value
Full name	Nicotinamide Adenine Dinucleotide (oxidised form: NAD+)
Type	Coenzyme (dinucleotide); not a peptide
Molecular weight	~663 Da
Half-life	Variable; plasma half-life is short (minutes); intracellular turnover varies by tissue
Common reported doses	250–1,000 mg IV or SubQ; 500–1,000 mg/day oral precursors (NMN, NR)
Administration routes	Intravenous, subcutaneous, oral (as precursors NMN or NR)
Storage	Stable at room temperature in sealed container; protect from light and moisture

Overview

NAD+ serves two primary roles in cell biology: it is a hydride-transfer agent in oxidation- reduction reactions central to energy metabolism, and it is a substrate consumed by regulatory enzymes including sirtuins (SIRT1–7), poly(ADP-ribose) polymerases (PARPs), and CD38.

Cellular NAD+ levels decline with age — a reduction that has been linked in animal research to impaired mitochondrial function, reduced DNA repair capacity, declining sirtuin activity, and increased susceptibility to metabolic and inflammatory stress. This age-related decline forms the primary rationale for NAD+ supplementation research.

Research has investigated NAD+ and its precursors for potential roles in:

Cellular energy metabolism: NAD+ is essential for glycolysis, the tricarboxylic acid (TCA) cycle, and oxidative phosphorylation. Restoring NAD+ levels is proposed to improve mitochondrial efficiency in aged or metabolically stressed cells
Sirtuin activation: Sirtuins are NAD+-dependent deacylases with roles in gene regulation, DNA repair, mitochondrial biogenesis, and inflammation modulation. SIRT1, SIRT3, and SIRT6 have received particular research attention in the context of ageing
DNA repair: PARP enzymes consume NAD+ during DNA single-strand break repair. Adequate NAD+ is proposed to support genomic stability, particularly in the context of age-related accumulation of DNA damage
Cognitive function: Animal studies have reported neuroprotective effects of NAD+ precursor supplementation. Human pilot data has reported improvements in some cognitive markers

Precursor distinction: Oral NAD+ is poorly absorbed in its intact form due to limited intestinal transport. Most oral supplementation research uses NAD+ precursors:

NMN (Nicotinamide Mononucleotide): One step upstream from NAD+; enters cells via the Slc12a8 transporter and is phosphorylated to NAD+
NR (Nicotinamide Riboside): Two steps upstream; converted to NMN and then NAD+

Reported Protocols

The following information represents commonly reported research approaches. These are not medical recommendations.

Intravenous Protocol

Intravenous administration bypasses gut absorption limitations and is reported to produce rapid NAD+ repletion. Commonly reported IV research doses range from 250 mg to 1,000 mg per session, administered over 1–4 hours.

Frequency: IV sessions are commonly reported weekly or monthly in anecdotal research accounts, rather than daily, due to the practical constraints of IV administration
Rate: Slow infusion is strongly emphasised in research accounts; rapid IV infusion is associated with pronounced transient side effects (see below)

Subcutaneous Protocol

Subcutaneous NAD+ is reported in research contexts as an alternative to IV when clinical infusion is not practical. Commonly reported doses range from 100 mg to 500 mg per injection. Subcutaneous NAD+ is reported to be associated with significant injection site discomfort due to the acidic pH of NAD+ solutions.

Oral Precursor Protocol

The most accessible approach in research contexts involves oral NMN or NR supplementation:

NMN: Commonly reported doses range from 500 mg to 1,000 mg per day; sublingual delivery is described in some research accounts to improve absorption
NR: Commonly reported doses range from 300 mg to 1,000 mg per day

Reported Effects

The following effects have been reported in preclinical research and human studies. This list reflects the research landscape, not confirmed outcomes for all individuals.

NAD+ Level Restoration

Human clinical trials with NMN and NR have consistently reported statistically significant increases in whole-blood or skeletal muscle NAD+ levels compared to placebo. Whether this increase translates to meaningful clinical benefit remains an active area of investigation.

Insulin Sensitivity

A randomised controlled trial (Yoshino et al., 2021) reported that NMN supplementation increased muscle insulin sensitivity in postmenopausal women with prediabetes. This is among the better-controlled human studies in the field.

Cognitive and Neurological Effects

Animal studies have reported neuroprotective and cognitive-enhancing effects of NAD+ precursor supplementation. Human pilot data has reported improvements in some cognitive markers in older adults. Larger controlled trials are ongoing.

Cardiovascular Markers

Some human trials with NR have reported reductions in inflammatory markers and improvements in blood pressure. The clinical significance of these findings is under investigation.

Fatigue and Energy

Anecdotal reports in research contexts very frequently describe improved energy levels and reduced fatigue following NAD+ supplementation (both IV and oral). Controlled trial data on subjective energy outcomes is limited.

Reported Side Effects

Reported side effects in research and anecdotal accounts include the following.

Side Effect	Frequency Reported
Flushing, warmth (IV; rate-dependent)	Very common with rapid IV infusion
Nausea (IV)	Common with rapid IV infusion; less common with slow infusion
Headache (IV)	Common, particularly at higher doses
Chest tightness (IV, transient)	Occasionally reported; rate-dependent
Injection site pain/inflammation (SubQ)	Very common; NAD+ solutions are irritating to tissue
GI discomfort (oral NR/NMN)	Occasionally reported
Flushing (oral NR; dose-dependent)	Occasionally reported at higher doses

IV administration note: Rapid intravenous infusion of NAD+ is consistently associated with transient but pronounced symptoms including flushing, chest discomfort, nausea, and headache. These are reported to resolve when the infusion rate is slowed. Slow infusion (2–4 hours) is strongly described in research accounts as the approach to minimising these effects.

Storage & Handling

Dry powder (NMN/NR): Stable at room temperature in a sealed container; protect from light, heat, and moisture
IV/SubQ solutions: Prepare fresh when possible; NAD+ solutions are acidic (pH ~2-3) and are best prepared under sterile conditions immediately before use
Refrigerator (2–8°C): Preferred for prepared solutions; use within 24–48 hours
Light sensitivity: NAD+ is light-sensitive; protect solutions from direct light

Frequently Asked Questions

If NAD+ is not a peptide, why is it covered here? NAD+ supplementation — particularly via IV and subcutaneous routes — is closely intertwined with the peptide research community. It is commonly sourced, discussed, and used alongside compounds such as Epitalon, GHK-Cu, MOTS-c, and SS-31 in longevity-focused research contexts. Its mechanisms (sirtuin activation, mitochondrial support) complement those of many researched peptides, and researchers frequently encounter it alongside peptide protocols.

What is the difference between NMN and NR? Both are NAD+ precursors. NMN (nicotinamide mononucleotide) is one step upstream from NAD+ and appears to enter cells directly via the Slc12a8 transporter. NR (nicotinamide riboside) is two steps upstream, requiring conversion to NMN before conversion to NAD+. Research comparing the two is ongoing; some studies suggest NMN may produce faster NAD+ repletion, but the clinical relevance of this difference is unclear.

Is IV NAD+ better than oral NMN? IV NAD+ is reported to raise blood NAD+ levels more rapidly and to higher peaks than oral precursors. Whether this translates to meaningfully different clinical outcomes is not established. IV administration requires clinical infrastructure and carries greater procedural risk. Most longevity researchers without IV access use oral NMN or NR as a practical alternative.

Are there any serious risks with NAD+ supplementation? Serious adverse events from NAD+ precursor supplementation are not prominently reported in the trial literature at commonly studied doses. The main safety concern with IV administration is the rate-dependent cardiovascular symptoms described above, which are transient and resolve with slowed infusion. Theoretical concerns about NAD+ substrate availability for DNA repair enzymes (PARPs) in cancer contexts have been raised but not substantiated clinically.

Goals: Longevity · Metabolic Health · Cognitive Support · Neuroprotection

Class: Longevity Peptides

Comparisons: Epitalon vs NAD+

References & Further Reading

Rajman L, Chwalek K, Sinclair DA. (2018). Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metabolism, 27(3), 529–547. PubMed →
Yoshino M, et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 372(6547), 1224–1229. PubMed →
Martens CR, et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications, 9, 1286. PubMed →